Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for its…
Immunology
-
-
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion…
-
Sobi gains FDA approval for Gamifant to treat HLH/MAS
The US Food and Drug Administration (FDA) has approved Sobi's Gamifant (emapalumab) to treat adults and children with haemophagocytic lymphohistiocytosis…
-
Vor Bio back from brink with autoimmune drug deal rising to $4bn
A month and a half after winding operations and laying off almost all its staff, Vor Bio has emerged from…
-
US FDA approves GSK’s Benlysta autoinjector for lupus nephritis
The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years…
-
Harbour BioMed partners Otsuka on new T-cell therapy
Harbour BioMed has entered a strategic partnership with Otsuka Pharmaceutical focusing on the development of HBM7020, a B-cell maturation antigen…
-
DoH – Abu Dhabi and Sanofi link for vaccine development
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine…
-
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP)…
-
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster…
-
Vertex halts development of diabetes cell therapy after trial failure
Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device,…
